IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.

IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Short squeezes don't typically live up to their expectations.

This Biotech Skyrocketed 84% in 2 Days, But Is It Warranted?

MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its common stock, which includes the exercise of the underwriters' option to purchase additional shares in full, and pre-funded warrants to purchase 1,334,332 shares of its common stock. The public offering price of common stock was $90.00 per share and the public offering price of each pre-funded warrant was $89.99, with each pre-funded warrant having an exercise price of $0.01. The aggregate gross proceeds to IGM from the offering were approximately $230 million, before deducting the underwriting discounts and commissions and other offering expenses payable by IGM.

IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock at a price to the public of $90.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase shares of its common stock at a purchase price of $89.99 per each pre-funded warrant, which represents the per share public offering price of common stock less the $0.01 per share exercise price for each such pre-funded warrant. IGM expects to receive total gross proceeds of approximately $200 million from this offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM. In addition, IGM has granted the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants in the offering will be sold by IGM. The offering is expected to close on or about December 11, 2020, subject to satisfaction of customary closing conditions.

IGM Announces Pricing of Upsized $200 million Public Offering

- 9 of 14 P atients S howed R eduction in T umor S ize, I ncluding T wo R ecently R eported C omplete R esponses -

IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin's Lymphoma at 2020 ASH Annual Meeting

MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Company's Phase 1 trial evaluating IGM-2323 at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting

MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial D ata from Phase 1 T rial of IGM-2323 in R elapsed/ r efractory N on-Hodgkin's L ymphoma to be Presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December -

IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update

- Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation - - Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation -

IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin's Lymphoma at 2020 ASH Annual Meeting

MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-8444, an IgM antibody targeting the Death Receptor 5 (DR5) protein, in patients with solid cancers and non-Hodgkin’s lymphoma.

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma

- Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies - - Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies -

AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration

Analysts also positive on Charles River, Gilead and Horizon Therapeutics

Jeffries Rates IGM Biosciences a Buy in Health Care Sector

IGM Biosciences (IGMS) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

IGM Biosciences (IGMS) Catches Eye: Stock Jumps 8.7%

Charles River Laboratories

Gilead Sciences

Horizon Pharma

The firms that we cover on Wall Street increasingly are starting to agree that the volatility the stock market is encountering now, and the beating the economy has taken this year, should continue to fade in the fourth quarter of 2020 and especially into 2021.

Jefferies Top Growth Stocks to Buy Include 4 Red-Hot Health Care Companies

Keurig Dr Pepper Inc

Xerox

Avis Budget Group

Golub Capital BDC

Kodiak Sciences Inc

  Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.

Notable Insider Buys Last Week: Keurig Dr Pepper, Xerox And More

MOUNTAIN VIEW, Calif., Sept.  02, 2020  (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor conferences:

IGM Biosciences to Present at Four Upcoming Investor Conferences

­IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter ended June 30, 2020 and provided an update on recent developments.

IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 at 1:45 p.m. ET.

IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

- Companies to utilize proprietary platforms to discover, develop, and manufacture potential  therapeutic antibodies to combat ongoing COVID-19 pandemic -

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19

Bicycle Therapeutics Plc - ADR

BioXcel Therapeutics

Clinical trial successes could send shares of these drugmakers screaming higher.

3 Ultra-Risky Biotech Stocks That Could Make You Filthy Rich

IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2019 Results - Earnings Call Transcript

Avid Bioservices

Endo International

Illumina

IVERIC bio Inc

Mylan

Neovasc

Pacira Pharmaceuticals

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

- Expert in the research and development of apoptotic pathways and antibody drug conjugates - - Expert in the research and development of apoptotic pathways and antibody drug conjugates -

IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

Beyond Meat

Cortexyme Inc

Inmode Ltd

Karuna Therapeutics Inc

Nextcure

Palomar

Shockwave Medical

Turning Point Therapeutics

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who didn’t buy into the hype of more familiar names like Uber or Lyft.

Non-Household Names Topped the List of IPO Winners in 2019

News for IGM Biosciences Inc Stock (IGMS)